Thera-SAbDab

TORIPALIMAB

>   Structural Summary
TherapeuticToripalimab
TargetPDCD1
Heavy ChainQGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS
Light ChainDVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK
100% seqID Fv Structure6jbt [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedFudan University, Peking University, Shanghai Junshi Biosciences, Sun Yat-Sen University
Conditions ApprovedMalignant melanoma
Conditions ActiveNasopharyngeal cancer, Oesophageal cancer, Biliary cancer, Gastric cancer, Non-small cell lung cancer, Solid tumours, Urogenital cancer, Head and neck cancer, Alveolar soft part sarcoma, Breast cancer, Cancer, Liver cancer, Lymphoma, Neuroendocrine tumours, Renal cancer
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]